Sirnaomics Enters Partnership with Walvax Biotechnology to Co-Develop Its Antiviral RNAi Therapeutic Product Candidate STP702
Published: Apr 29, 2021 GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 29, 2021 /PRNewswire/ -- Sirnaomics (Suzhou) Co. Ltd., a subsidiary of Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases and viral infections, announced today that the company has entered into a partnership agreement with Walvax Biotechnology (Walvax) for the co-development of its anti-influenza siRNA therapeutic product candidate STP702. Sirnaomics will out-license to Walvax the exclusive development and commercialization...
Source: biospace.com